AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I
AC Immune Gets €28M from Eli Lilly as Alzheimer’s Drug Hits Phase I
Dec 17, 2019
This article highlights the progress made in the AC Immune/Eli Lilly collaboration to develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases.